Program
Allocetra
Its studies are mostly in Osteoarthritis, Knee · Osteoarthritis · Arthritis, Psoriatic, led by Enlivex Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Enlivex Therapeutics | 31 open or running | phase 2since Jan 22, 2024 | Jan 22, 2024 | Feb 2027phase 2 · NCT07580716 |
Also a collaborator on its studies: nordic-bioscience-clinical-development.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 22, 2024First study: phase 2 study in Osteoarthritis, KneeFirst studyNCT06233474 · 134 enrolled · Denmark, Israel, Moldova
- Jul 7, 2024Phase 1 study in Arthritis, PsoriaticNCT06522035 · 5 enrolled · Israel
- Apr 23, 2026Phase 2 study in OsteoarthritisNCT07580716 · 182 planned · United States, Denmark, Poland
Ahead
- Feb 2027Primary completion: phase 2 study in OsteoarthritisNCT07580716
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07580716Osteoarthritis · United States, Denmark, Poland | 2 | Recruiting | Feb 2027 | 182 |
| NCT06522035Arthritis, Psoriatic · Israel | 1 | Terminated | Oct 20, 2025 | 5 |
| NCT06233474Osteoarthritis, Knee · Denmark, Israel, Moldova | 2 | Completed | Mar 15, 2026 | 134 |
How it is read
Names in the registry
- “Allocetra”, 3 entries
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 1 study
- Osteoarthritis, 1 study
- Arthritis, Psoriatic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.